AtriCure, Inc.

Good afternoon and welcome to ATRA CARES first quarter 2026 earnings conference call. This call is being recorded for replay purposes and at this time all participants are in listen only mode. We will be facilitating a question and answer session following prepared remarks from ATRA CARES management. I would now like to turn the call over to Marissa Bleich from the Gil Martin Group for a few introductory comments.

Great, thank you.

By now, you should have received a copy of the earnings press release. If you have not received a copy, please call 513-644-4484 to have one emailed to you. Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond HRCUR's control including risks and uncertainties described from time to time in Atricure's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for Atricure's franchises and growth initiatives, future product approvals and clearances, competition, reimbursement, and clinical trial enrollment and outcomes. Atricure's results may differ materially from those projected. Matricure undertakes no obligation to publicly update any forward-looking statement. Additionally, we refer to non-GAAP financial measures, specifically constant currency revenue, adjusted EBITDA, and adjusted loss per share. A reconciliation of these non-GAAP financial measures with the most directly comparable GAAP measures is included in our press release, which is available on our website. And with that, I would like to turn the call over to Mike Carroll, President and Chief Executive Officer.